De Novo treatment of diffuse large B-cell lymphoma with Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial.
Authors
Fields, PTownsend, W
Webb, A
Counsell, N
Pocock, C
Smith, P
Jack, A
El-Mehidi, N
Johnson, P
Radford, John A
Linch, D
Cunnningham, D
Affiliation
Guys and St Thomas' and King's College Hospitals, London, UK.Issue Date
2013-11-12
Metadata
Show full item recordAbstract
The treatment of patients with diffuse large B-cell lymphoma (DLBCL) with cardiac comorbidity is problematic, because this group may not be able to receive anthracycline-containing chemoimmunotherapy. We designed a single-arm phase II multicenter trial of rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) in patients considered unfit for anthracycline-containing chemoimmunotherapy because of cardiac comorbidity.Citation
De Novo treatment of diffuse large B-cell lymphoma with Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial. 2013: J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2013.49.7586PubMed ID
24220559Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2013.49.7586
Scopus Count
Collections
Related articles
- Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
- Authors: Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, Greil R
- Issue date: 2016 May
- Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
- Authors: Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D
- Issue date: 2013 May 25
- Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
- Authors: Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte
- Issue date: 2011 Nov 26
- Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.
- Authors: Corazzelli G, Frigeri F, Arcamone M, Lucania A, Rosariavilla M, Morelli E, Amore A, Capobianco G, Caronna A, Becchimanzi C, Volzone F, Marcacci G, Russo F, De Filippi R, Mastrullo L, Pinto A
- Issue date: 2011 Sep
- Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.
- Authors: Djebbari F, Browning JA, Stanton L, Booth S, Hildyard C, Willan J, Bosworth J, Vora SM, Hatton CSR, Collins GP, Eyre TA
- Issue date: 2019 Sep